title: In vitro activity of E-1040, a 3-substituted cephalosporin, against pathogens from cystic fibrosis sputum.
abstract: On the basis of preliminary in vitro data, we evaluated E-1040, a new cephalosporin, against 188 cystic fibrosis (CF) sputum isolates obtained from 26 CF centers in the United States. These isolates included mucoid and nonmucoid Pseudomonas aeruginosa, Pseudomonas cepacia, Staphylococcus aureus, Haemophilus influenzae, and Escherichia coli. In addition to MICs measured under standard conditions, selected isolates were tested at various pH values, inoculum sizes, and diluent (CF serum and sputum) conditions. E-1040 activities (MICs for 50 and 90% of the strains) against the isolates were as follows: P. aeruginosa (mucoid and nonmucoid), 1 and 4 micrograms/ml; P. cepacia, 4 and 16 micrograms/ml; S. aureus, 8 and 8 micrograms/ml; H. influenzae, 1 and 4 micrograms/ml; and E. coli, less than or equal to 0.12 and less than or equal to 0.12 microgram/ml. E-1040 activity against mucoid P. aeruginosa was 4-fold greater than that of aztreonam, 16-fold greater than that of ceftazidime, and 32-fold greater than that of piperacillin. E-1040 was similar to other broad-spectrum cephalosporins against S. aureus, H. influenzae, and E. coli. Bactericidal activity was less than or equal to 1 dilution of MIC for 88% of the strains, although kinetic studies with mucoid strains of P. aeruginosa demonstrated effective killing only at eight times the MIC. Variations in pH from 5 to 8, in inoculum size from 10(3) to 10(7) CFU/ml, and in diluent (CF serum or CF sputum) did not affect E-1040 activity.
authors.affiliation: Department of Pediatrics, Memorial Miller Children's Hospital, Long Beach, California 90801.
authors.forename: H R
authors.initials: HR
authors.lastname: Stutman
authors.forename: J C
authors.initials: JC
authors.lastname: Akaniro
authors.forename: C E
authors.initials: CE
authors.lastname: Vidaurre
authors.forename: M I
authors.initials: MI
authors.lastname: Marks
mesh_terms: D001419:Bacteria / Q000187:drug effects* / Q000254:growth & development; D002511:Cephalosporins / Q000494:pharmacology*; D003550:Cystic Fibrosis / Q000382:microbiology*; D007700:Kinetics; D008826:Microbial Sensitivity Tests; D013183:Sputum / Q000382:microbiology*
chemical_list: D002511:Cephalosporins; C056494:cefclidin